Te Bao Biotech: ACT201 injection clinical trial application accepted for review.

Tebao Bio announcement, the company has recently received the approval and issuance of the "Acceptance Notice" from the National Medical Products Administration for the clinical trial application of ACT201 injection. ACT201 injection is an innovative antisense oligonucleotide drug with significant improvement in RNase H-mediated antiviral activity, moderate enhancement of human TLR8 agonist activity, fewer off-target effects, and improved liver and kidney distribution ratio of ASO. Its clinical trial application has been successfully included in the "30-day channel" specified by the National Medical Products Administration.